Gilead’s Elvitegravir Phase III Could Face Challenges With Novel HIV Comparator
This article was originally published in The Pink Sheet Daily
Executive Summary
Integrase inhibitor will likely need to be compared to active control such as investigational maraviroc or raltegravir in Phase III, firm reports.
You may also be interested in...
Gilead Executive VP-R&D Norbert Bischofberger: An Interview With “The Pink Sheet” DAILY (Part 2 of 3)
Bischofberger discusses how darusentan could complement recently approved Letairis in the hypertension market, and how Gilead plans to develop its integrase inhibitor elvitegravir, a potential competitor to Merck’s Isentress.
Gilead Executive VP-R&D Norbert Bischofberger: An Interview With “The Pink Sheet” DAILY (Part 2 of 3)
Bischofberger discusses how darusentan could complement recently approved Letairis in the hypertension market, and how Gilead plans to develop its integrase inhibitor elvitegravir, a potential competitor to Merck’s Isentress.
Merck’s Novel HIV Drug Isentress Granted Six-Month FDA Review
First-in-class integrase inhibitor could see a mid-October approval.